期刊
FRONTIERS IN ONCOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.929012
关键词
novel agents; brentuximab vedotin; nivolumab; pembrolizumab; relapsed and refractory classical hodgkin lymphoma
类别
资金
- Support Program for Science and Technology Department of Sichuan Province [2021YFS0228, 2021YFS0230]
- West China Hospital, Sichuan University [ZYJC21033]
Classical Hodgkin lymphoma, the most common type of HL, mainly affects people in certain age groups. A significant proportion of patients with refractory or relapsed cHL do not respond well to treatment. Exploring new predictive strategies and treatment measures may help improve the cure rate for these patients.
Classical Hodgkin lymphoma (cHL) is the most common type of HL that occurs mainly in people aged between 15-30 and over 55 years. Although its general prognosis is favorable, 10%-30% of patients with cHL will ultimately develop relapsed or refractory disease (r/r cHL). Improving the cure rate of r/r cHL has proven to be challenging. Some novel agents, such as brentuximab vedotin and immune checkpoint inhibitors, which have been used in conventional regimens for patients with r/r cHL in the past decade, have been shown to have good curative effects. This paper reviews the conventional regimens for patients with r/r cHL and focuses on the newest clinical trials and treatment measures to prolong prognosis and reduce adverse events. The evaluation of prognosis plays a vital role in analyzing the risk of relapse or disease progression; thus, finding new predictive strategies may help treat patients with r/r cHL more efficaciously.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据